Treatment strategies for endothelial dysfunction in CRPS patients include the substitution of nitric oxide with ISDN, inhibition of PDE5, substitution of ADMA, or blockage of ETA receptors. This evidence concerns the gene PDE5A and complex regional pain syndrome.